Boston Life Sciences, Inc. Announces The Issuance Of A U.S. Patent Licensed To BLSI By Harvard Et Al That Covers Methods For The Diagnosis Of ADHD

Boston Life
Sciences, Inc. (Nasdaq: BLSI) announces that the U.S. Patent and Trademark
Office has issued a patent to the President and Fellows of Harvard College,
the General Hospital Corporation and Organix, Inc. that covers methods of
diagnosing and monitoring attention deficit hyperactivity disorder (ADHD)
by assessing the level of dopamine transporter (DAT) in at least one region
of a patient's central nervous system. The patent is exclusively licensed
to BLSI under a worldwide licensing arrangement between BLSI and Harvard
University. The patent is based on the work of the inventors, Dr. Bertha
Madras of Harvard, Dr. Peter Meltzer of Organix, Inc., and Dr. Alan
Fischman of Massachusetts General Hospital. Both Dr. Fischman and Dr.
Meltzer serve as advisors to BLSI. The patent claims a variety of
diagnostic and monitoring methods for assessing ADHD utilizing labeled
compounds that bind to the dopamine transporter and are measured using any
imaging technique including single photon emission computed tomography
(SPECT) and positron emission tomography (PET). An example of a compound
covered by the patent is the Company's ALTROPANE(R) molecular imaging agent
currently in Phase II clinical trials as an aid to ADHD diagnosis. The
Company is currently analyzing imaging results and clinical data, both of
which were obtained from patients enrolled to-date, to verify findings in
prior studies and ensure that the trial design and quantification
algorithms are appropriate.


In addition to methods used to objectively diagnose ADHD in adults or
children, the patent covers methods that could enable physicians to
determine the most effective ADHD drug treatment and/or dosage level for an
individual patient, monitor the long-term progress of treatment for ADHD,
and aid in identifying individuals at risk for ADHD.


Mark Hurtt, BLSI's Chief Medical Officer, comments, "The use of imaging
techniques and dopamine transporter specific imaging agents has the
potential to provide an objective, biologically-based diagnosis for ADHD.
We are very pleased with the potential scope of this patent. We believe
that the new patent enhances our position in this significant area of
medical need. According to the Centers for Disease Control, between 3% and
7% of school-aged children and 2 to 4% of adults have been diagnosed with
ADHD. We believe that imaging agents may assist physicians in confirming a
diagnosis, resolving conflicting diagnoses, calling into question a
diagnosis or non-diagnosis of ADHD, or selecting medication."


About the Patent


The new patent issued on July 25, 2006 under U.S. patent number
7,081,238 B2. The application was filed on August 17, 2001 and, under 35
U.S.C. 154(b) had 142 days added to its duration.



About ADHD


According to the Center for Disease Control, Attention Deficit
Hyperactivity Disorder (ADHD) is one of the most common neurobehavioral
disorders of childhood and can persist through adolescence and into
adulthood. ADHD affects almost 4 million school-aged children and is among
the fastest growing neurobehavioral disorders in adults with an estimated
2-4% of Americans affected. ADHD is now diagnosed by medical and mental
health professionals with a set of behavioral criteria but there is
currently no objective biological test.















About BLSI


Boston Life Sciences, Inc. (BLSI) is engaged in the research and
clinical development of diagnostic and therapeutic products for central
nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in
Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS)
and in Phase II clinical trials for the diagnosis of Attention Deficit
Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS
programs include INOSINE for the treatment of stroke, a DAT blocker for the
treatment of Parkinson's disease and a second generation technetium-based
molecular imaging agent for PS and ADHD. BLSI's current research
collaborations include Harvard Medical School and Children's Hospital
Boston.


Safe Harbor


The foregoing release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward- looking statements include statements regarding Boston Life
Sciences' future expectations, beliefs, intentions, goals, strategies,
plans or prospects regarding the future, including the Company's current
and future programs relating to ADHD, licensing arrangements by the Company
for certain intellectual property, and the scope of, the methods covered
by, uses and potential uses of such intellectual property. Forward-looking
statements can be identified by terminology such as "anticipate,"
"believe," "could," "could increase the likelihood," "estimate," "expect,"
"intend," "is planned," "may," "should," "will," "will enable," "would be
expected," "look forward," "may provide," "would" or similar terms,
variations of such terms or the negative of those terms. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors including those risks, uncertainties and factors referred
to in the Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2006 filed with the Securities and Exchange Commission under the
section "Risk Factors," as well as other documents that may be filed by
Boston Life Sciences from time to time with the Securities and Exchange
Commission. As a result of such risks, uncertainties and factors, the
Company's actual results may differ materially from any future results,
performance or achievements discussed in or implied by the forward-looking
statements contained herein. Boston Life Sciences is providing the
information in this press release as of this date and assumes no
obligations to update the information in this press release.



Boston Life Sciences, Inc.

bostonlifesciences/